• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Stock

Elon Musk’s Neuralink raises $650 million in fresh capital

by June 3, 2025
written by June 3, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
House Dems urge GOP to condemn DHS for handcuffing Rep Nadler staffer, order Noem to testify
next post
Trump and Melania to headline power-player packed Kennedy Center opening night

related articles

Lego hits record revenue in first half of...

August 28, 2025

Google has eliminated 35% of managers overseeing small...

August 28, 2025

Cracker Barrel will go back to old logo...

August 27, 2025

Frontier Airlines goes after struggling rival Spirit’s customers...

August 27, 2025

What a stake in Intel could mean for...

August 26, 2025

Cracker Barrel assures customers its values remain the...

August 26, 2025

U.S. could take stakes in more firms, White...

August 26, 2025

Keurig Dr Pepper to buy Peet’s Coffee owner...

August 25, 2025

What’s the secret of their success? Summer camp

August 25, 2025

From American Eagle to Swatch, why brands seem...

August 25, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Dems renew push for limiting presidential clemency powers after Hunter Biden pardon

    December 4, 2024
  • Ukraine accepts deal, says Rubio: ‘We’ll take this to the Russians’

    March 11, 2025
  • The dollar index has a new opportunity to start a recovery

    August 26, 2024
  • Who is Norm Eisen? Meet the anti-Trump attorney repping FBI agents suing the DOJ

    February 8, 2025
  • Hezbollah drone attack in Israel wounds over 60 people, some critically: reports

    October 13, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,838)
  • Investing (634)
  • Stock (906)

Latest Posts

  • Harris paid Oprah $1 million in failed bid to help campaign: report

    November 11, 2024
  • House Freedom Caucus heading to White House after delay play on Trump’s ‘big, beautiful bill’

    May 21, 2025
  • Nifty and German 40: Nifty strengthens bullish momentum

    August 20, 2024

Recent Posts

  • House Republicans lament Trump’s ‘terrible’ debate performance: ‘Let her get under his skin’

    September 12, 2024
  • Trump buries Biden foreign policy in first 100 days

    April 29, 2025
  • Mike Johnson mounts 20-state blitz to keep House red as GOP braces for Harris VP reveal

    August 5, 2024

Editor’s Pick

  • Republican senator claims RFK Jr. mRNA vaccine decision undermines Trump agenda

    August 7, 2025
  • Solana and Cardano: Solana moves above the weekend high

    August 20, 2024
  • Scalise to focus on Trump’s compassion in RNC speech, says assassination attempt brought back 2017 ’emotions’

    July 17, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock